21 May 2009
Individualization of immunosuppressive therapy
B D KahanAnn Transplant 2009; 14(1): 20-20 :: ID: 880272
Abstract
This "Meet the Professor" discussion session is divided into four segments:
pre-morbid donor features (5 minutes), pre-transplant morbid donor events
(5 minutes), pre-transplant characteristics of potential recipients (10 minutes), and post-transplant recipient events (15 minutes). Each section will include a brief presentation and questions. The pre-morbid donor features include age over 50 years, pharmacogenomics, kidney size, and concomitant diseases. The morbid donor events include the etiology of death, preretrieval pathophysiologic events and intraoperative events. The pretransplant recipient characteristics are gender, age, ethnicity, medical regimen, pharmacogenomics, unrecognized malignancy/infection, HLA mismatch, socioeconomic education level, donor source, and immune responder status. The post-transplant recipient events include cold ischemia time, concomitant drug therapies, complications, chronic allograft disease, rejection episodes and non-compliance. Literature citations will be provided and informal discussion offered after the session.
Keywords: immunosuppressive therapy
In Press
Case report
Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case SeriesAnn Transplant In Press; DOI: 10.12659/AOT.951715
Original article
Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952251
Original article
The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...Ann Transplant In Press; DOI: 10.12659/AOT.952031
Original article
Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...Ann Transplant In Press; DOI: 10.12659/AOT.953143
Most Viewed Current Articles
24 Aug 2021 : Review article 20,545
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 16,641
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
05 Apr 2022 : Original article 15,898
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 15,796
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988






